These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 12497581)
1. Using splines to detect changes in PSA doubling times. Guess B; Jennrich R; Johnson H; Redheffer R; Scholz M Prostate; 2003 Feb; 54(2):88-94. PubMed ID: 12497581 [TBL] [Abstract][Full Text] [Related]
2. Critical analysis of prostate-specific antigen doubling time calculation methodology. Svatek RS; Shulman M; Choudhary PK; Benaim E Cancer; 2006 Mar; 106(5):1047-53. PubMed ID: 16456812 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Lee AK; Levy LB; Cheung R; Kuban D Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415 [TBL] [Abstract][Full Text] [Related]
4. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762 [TBL] [Abstract][Full Text] [Related]
5. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836 [TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481 [TBL] [Abstract][Full Text] [Related]
8. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. Bellera CA; Hanley JA; Joseph L; Albertsen PC Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279 [TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Shulman MJ; Karam JA; Benaim EA Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890 [TBL] [Abstract][Full Text] [Related]
10. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM; Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837 [TBL] [Abstract][Full Text] [Related]
11. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models. Symon Z; Kundel Y; Sadetzki S; Oberman B; Ramon J; Laufer M; Catane R; Pfeffer MR Am J Clin Oncol; 2006 Oct; 29(5):446-50. PubMed ID: 17023777 [TBL] [Abstract][Full Text] [Related]